Join us as we discuss the struggles and successes of securing funding for clinical trials and other research translation efforts. Hear from representatives from industry, competitive funding bodies and seasoned investigators.
Learn invaluable insights and strategies to elevate the calibre of your funding applications, setting you on a trajectory towards success.
We’ll cover the following important topics over 3 sessions:
Join us for a Q&A panel session and networking opportunity with experts from Moderna, Sanofi and Stryker. This event is designed to bridge the gap between researchers and industry leaders, with a special focus on clinical trials.
The event format is a moderated Q&A session with a panel of experts.
Craig Rayner
Director of the Regional Centre for Respiratory, Medicines and Tropical Diseases, Moderna
Craig is the Director of the Regional Centre for Respiratory Medicines and Tropical Diseases at Moderna in Melbourne. He is also an Adjunct Professor and distinguished alumnus at Monash University Institute of Pharmaceutical sciences with >120 peer reviewed scientific articles/book chapters primarily relating to clinical pharmacology, and global health and infectious diseases. His experience spans Europe, the USA, and Australia, including roles with Roche and CSL. He was the founding CEO of d3 Medicine and led Certara through a US$768 million Nasdaq listing to a US$7 billion market cap. He has held leadership roles in developing and approving several new medicines.
In the past 3 years, Craig focused on COVID-19, collaborating with the WHO, Gates Foundation and COVID-19 Therapeutics Accelerator. He led Certara’s COVID-19 response, supporting >40 therapeutics and vaccine programs. He was a senior co-investigator on the TOGETHER trial and co-authored 24 COVID-19 related articles in journals like Science, Annals of Internal Medicine, NEJM, and Lancet.
Michelle Williams
Strategic Partnership Lead, Sanofi
Before transitioning to the industry, Michelle earned a PhD in Cellular and Molecular Biology, specialising in cardiovascular research. In her current role as the partnerships lead at the Translational Science Hub based in Brisbane, Michelle collaborates with a team of healthcare professionals to translate scientific discoveries into practical applications. The primary focus is on vaccine development, where she fosters collaborations between Australian scientists and research teams within Sanofi to advance mRNA technology. She has has over 15 years of experience in clinical trials working from first in human to late phase trials within the biotech and pharma companies in a number of therapeutic areas. She has also led digital clinical initiatives including the use of electronic health records for clinical trial site identification and patient recruitment.
Mark Luhovy, MD, PMP is currently Digital Health Manager for the Stryker Australia R&D Lab in Brisbane. He is a medical doctor and biomedical engineer, former Johnson & Johnson consultant and Principal of BioEnginuity, a strategic digital healthcare and biotech consulting company he founded in 2018. Mark has been in the medical device industry since 2005 including ten years prior to attending medical school at the University of Queensland, with previous roles of increasing responsibility at St. Jude Medical, J&J and Draeger Medical. He is an active contributing member of the Medical Technology Association of Australia (MTAA) Digital Health Advisory Group (DHAG).
Receive our eNews
Connect with us
Quicklinks
Health Translation Queensland acknowledges the Traditional Owners and their custodianship of the lands on which we live, work, and play. We pay our respects to their Ancestors and their Descendants, who continue cultural and spiritual connections to Country. We recognise their valuable contributions to Australian and global society.
